logo

Zogenix, Inc. (ZGNX)



Trade ZGNX now with
  Date
  Headline
7/12/2018 7:05:15 AM Zogenix Announces Positive Top-line Results From Second Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome
6/1/2018 4:38:00 PM Zogenix Reports Granting Of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
4/25/2018 8:14:05 AM Zogeni Presents New Safety Data From First Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome
2/6/2018 8:06:57 AM Zogenix Reports Receipt Of FDA Breakthrough Therapy Designation For ZX008 In Dravet Syndrome
8/10/2011 4:30:44 PM Zogenix, Inc. (ZGNX) Has Lowered Its FY11 Revenue Estimate To $43 - $47 Mln From $46 - $52 Mln
  
 
>